W. Fazzone

发表

Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage

H. Lenz, P. Wilson, W. Fazzone, 2008, Nucleic acids research.

Molecular determinants of irinotecan efficacy

H. Lenz, K. Danenberg, W. Fazzone, 2006, International journal of cancer.

The dual EGFR/HER‐2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN‐38

H. Lenz, P. Wilson, W. Fazzone, 2009, International journal of cancer.

Novel opportunities for thymidylate metabolism as a therapeutic target

N. Neamati, J. Deng, P. Wilson, 2008, Molecular Cancer Therapeutics.

ABCB1, SLCO1B1 and UGT1A1 Gene Polymorphisms Are Associated with Toxicity Line Irinotecan

H. Lenz, W. Fazzone, R. Ladner, 2007 .

ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.

H. Lenz, W. Fazzone, R. Ladner, 2007, Drug metabolism letters.

Identification of sequence determinants of human nuclear dUTPase isoform localization.

W. Fazzone, R. Ladner, F. Lynch, 2003, Experimental cell research.

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

H. Lenz, A. El-Khoueiry, P. Wilson, 2011, Cancer research.

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

S. Groshen, H. Lenz, A. El-Khoueiry, 2010, Cancer Chemotherapy and Pharmacology.

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

Susan Groshen, S. Groshen, H. Lenz, 2009, BMC Medical Genomics.

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells

H. Lenz, P. Wilson, W. Fazzone, 2009, International journal of cancer.

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer

Susan Groshen, Alexandra Pohl, Dongyun Yang, 2008, Pharmacogenetics and genomics.

Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer.

C. Haiman, H. Lenz, A. El-Khoueiry, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab

S. Groshen, H. Lenz, W. Fazzone, 2006, Pharmacogenetics and genomics.

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

H. Lenz, A. El-Khoueiry, P. Wilson, 2011, Cancer research.

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

P. Wilson, W. Fazzone, M. LaBonte, 2009, BMC Medical Genomics.

Polymorphism in sodium-channel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin.

H. Lenz, A. El-Khoueiry, W. Zhang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.